Navigation Links
Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A

BRISBANE, Australia, July 22 /PRNewswire-FirstCall/ -- Following a thorough review that concluded late yesterday, the Board of Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced that it had discontinued the PI-88 phase 3 study in liver cancer. Progen confirmed its strategic direction to develop its existing portfolio of compounds and the company will actively seek to acquire additional compounds and opportunities through Merger & Acquisition activity.

The strategic review was triggered by a recent accumulation of a number of factors that impacted the commercial return for the phase 3 PATHWAY trial.

The trial is unlikely to meet the forecast patient recruitment timetable and further significant delays were expected due to:

-- slower than expected regulatory processes in China, Korea and Vietnam;

-- slower than expected initiation of clinical sites;

-- slower than expected recruitment of patients into active sites; and

-- the recent launch of a competitive phase 3 trial, assessing Bayer/Onyx Nexavar(R) in the same indication.

Due to a lack of a global partner willing to meaningfully develop and commercialise PI-88, the commercial opportunity is much less than previously expected. Without a significant global partner contributing, Progen will be less able to expand into additional indications and exploit all potential PI-88 commercial opportunities.

These aspects would have delayed market entry significantly and seriously impacted on the commercial return of the phase 3 PATHWAY trial.

The next step is that Progen will seek expressions of interest in PI-88, at a regional level, initially from amongst those parties that had entered into Non-Disclosure Agreements and Due Diligence on PI-88.

The PI-88 trial had been facilitated through external agencies, and had resulted in 23 sites being opened for patient recruitment and 12 patients from 5 recruitment centres having been recruited to date. Existing patients receiving PI-88 will continue to receive the drug if they wish to do so, subject to regulatory approval. External costs of the trial in FY2008 are estimated at $9.8m. The cost of discontinuing this trial is estimated to be less than $4.0m.

As part of the strategic review, Progen has determined that the current phase 2b melanoma trial, will be completed but no further development in melanoma by Progen is anticipated at this stage. This trial is expected be finalised at an estimated additional cost of $300,000.

In addition, and as part of the strategic review, the Company has also decided to terminate further development of its phase 1 compound PI-166, based on a recent commercial assessment of the market and the approval of Nexavar(R) in this indication.

The Board of Progen has determined that it will increase its focus on the further development of molecules with high potential value.

Progen will focus its resources on aggressively pursuing its other compounds in development PG11047 (phase 1), the 500 series (late preclinical) and the epigenetics platform (early preclinical).

-- Progen has previously announced the phase 1 trial of compound PG11047, for patients with advanced cancers, which had been the subject of an earlier phase 1 trial. This extended trial is already showing positive tolerability/dosing profiles.

-- The 500 series is currently undergoing scale-up manufacture and animal safety studies.

-- The Board of Progen has confirmed that it will continue to expand its gene expression modification - epigenetic - compounds platform, added to Progen's technology platform through the CellGate acquisition.

In parallel, the Company will be actively pursuing merger and acquisition opportunities to expand its clinical stage pipeline.

Given its strong cash position, Progen will aggressively pursue M&A activities. As part of this process, Progen will announce in the next weeks the appointment of corporate advisers to assist with the identification of and initial discussion with potential acquisitions in Australia and the United States.

Cash Position as at 30 June 2008: $76.7m, excluding creditors and accruals of $6.2m (unaudited).

On behalf of the Board of Directors and Management,

Dr Mal Eutick


About Progen: Progen Pharmaceuticals is a globally focused biotechnology company committed to the discovery, development and commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has built a focus and strength in anti-cancer drug discovery and development. Progen targets the multiple mechanisms of cancer across its three technology platforms, angiogenesis, epigenetics and cell proliferation. Progen has operations in Australia and the US.

Contact Point:

Dr Mal Eutick


0416 177 772

Justus Homburg

CEO, Managing Director

T: +61 7 3842 3333

Linton Burns

Company Secretary

T: +61 7 3842 3333

Contact details:

Progen Pharmaceuticals Limited

ABN 82 010 975 612

PO Box 2403 Toowong Qld 4066

T: +61 7 3842 3333

F: +61 7 3720 9624


SOURCE Progen Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Presentation of Data on Progens Cancer Epigenetic Targets Platform
2. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
3. Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047
4. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
5. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
6. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Progen Announces PI-88 Phase 2 Lung Cancer Results
9. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of ... 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session on ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/27/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the ... LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making the ... a version of Asterisk that will receive not only security fixes, but feature ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD ... for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians ... directly from their electronic medical record (EMR) without the need for redundant patient ...
Breaking Medicine News(10 mins):